Astria Therapeutics, Inc. (NASDAQ:ATXS) Sees Large Increase in Short Interest

Astria Therapeutics, Inc. (NASDAQ:ATXS) saw a significant growth in short interest in January. As of January 15th, there was short interest totalling 3,370,000 shares, a growth of 25.7% from the December 31st total of 2,680,000 shares. Based on an average trading volume of 286,800 shares, the short-interest ratio is currently 11.8 days. Approximately 7.4% of the company’s stock are short sold.

Astria Therapeutics Stock Up 4.9 %

Shares of NASDAQ:ATXS traded up $0.37 on Friday, reaching $7.86. 457,247 shares of the company’s stock were exchanged, compared to its average volume of 308,953. Astria Therapeutics has a fifty-two week low of $7.16 and a fifty-two week high of $16.90. The business’s 50-day moving average is $8.97 and its two-hundred day moving average is $10.47. The firm has a market capitalization of $443.54 million, a price-to-earnings ratio of -3.76 and a beta of 0.70.

Hedge Funds Weigh In On Astria Therapeutics

A number of large investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP raised its position in shares of Astria Therapeutics by 1,043.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 146,158 shares of the biotechnology company’s stock worth $1,330,000 after purchasing an additional 133,379 shares during the period. Hsbc Holdings PLC acquired a new position in Astria Therapeutics during the 2nd quarter valued at about $171,000. Millennium Management LLC grew its position in Astria Therapeutics by 13.5% in the 2nd quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company’s stock worth $16,763,000 after purchasing an additional 218,518 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Astria Therapeutics in the second quarter valued at approximately $400,000. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Astria Therapeutics during the second quarter valued at approximately $2,561,000. Institutional investors own 98.98% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Oppenheimer boosted their price target on Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Thursday, November 14th. JMP Securities started coverage on shares of Astria Therapeutics in a research report on Friday. They set an “outperform” rating and a $26.00 price target for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a report on Thursday, January 23rd. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Astria Therapeutics presently has an average rating of “Buy” and a consensus price target of $25.67.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.